Global Alosetron Market, By Dosage type (0.5mg, 1mg), Applications (Chronic Irritable Bowel Syndrome, Visceral Pain, Gastrointestinal Diseases), Mode of Purchase (Prescription and Over the Counter), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights: Global Alosetron Market
Global Alosetron market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a healthy CAGR of 3.50% in the above-mentioned research forecast period.
Alosetron (Generic Name: Alosetron, Brand Name: Lotronex) is a drug which has been prescribed to treat women with Irritable Bowel Syndrome (IBS), having diarrhea as the main problem. Alosetron belongs to class 5-HT receptor antagonists. It is a pyrido [4,3-b] indole compound which consists of 5-methyl-1H-imidazole-4-ylmethyl group placed at the 2nd position. It acts as a serotenergic antagonist, an antiemetic and a gastrointestinal drug. The mechanism of action of 5-HT3 receptor antagonist is the prevention of emesis (vomiting) followed by the chemotherapy action. The receptor antagonist at 5-HT3 receptors on vagal afferent neurons, antagonizes the action of 5- hydroxytryptamine (5-HT), which initiates the nervous excitation of the gastrointestinal tract and 5-HT3 receptors in the central vomiting system it is responsible to reduce abdominal pain. Alosteron can be taken by oral route of administration. This prescription is strictly not recommended for use for children However, the side effects incurred by consumption of Alosetron are swelling in the stomach area, hemorrhoids and upset stomach. Unnecessary medication should be discarded in a safe way, so as to guarantee that pets, small children and other people do not utilize them. Lotrones was approved by Food and Drug Administration (FDA) in February 2000.
The rise in cases of irritable bowel syndrome, increased count of women geriatric population, the rise in health expenditure, presence of existing alosetron drugs, increased demand of oral tablets are the factors expected to drive the market growth. However, the presence of strict regulatory protocols, lack of awareness about the symptoms and prevention of irritable bowel syndrome, side effects caused due to consumption of alosetron and lack of sanitation are the restraints which are likely to hinder the market growth. The opportunities which are predicted to propel the market are the emerging markets, rise of untapped opportunities, increasing government and Research and Development activites for production of alosetron drugs and enhancement in healthcare architecture. The reluctance to consume the tablets, use of alternatives, drug recalls and the problems faced in supply chain and logistics for transportation of drugs to the requisite distribution channels are the challenges which are likely to tamper the global Alosetron market.
This Alosetron market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Alosetron Market Scope and Market Size
The Alosetron market is segmented on the basis of dosage type, application, mode of purchase and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of dosage type, the Alosetron market is segmented into 0.5mg, 1mg.
- On the basis of applications, the Alosetron market is segmented into chronic irritable bowel syndrome, visceral pain, gastro intestinal diseases.
- On the basis of mode of purchase, the Alosetron market is segmented into prescription and Over the Counter (OTC).
- On the basis of distribution channel, the Alosetron market is segmented into hospital pharmacies, retail pharmacies, online pharmacies.
Alosetron Market Country Level Analysis
Alosetron market is analysed and market size information is provided by country, dosage type, application, mode of purchase and distribution channel as referenced above.
The countries covered in the Alosetron market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
On geographical estimation, North America is expected to hold the largest market share due to the increased availability of alosetron drugs, rising prevalence of patients suffering from irritable bowel syndrome and presence of health policies are predicted to boost the market in the region. The prevalence of irritable bowel syndrome in North America is almost 10-15%. Asia-Pacific is expected to account for the fastest growing market due to upcoming clinics and hospitals, increased awareness about the symptoms of irritable bowel syndrome and safe medication of alosetron and good supply of drugs by the manufacturers.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Alosetron market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Alosetron Market Share Analysis
Alosetron market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to Alosetron market.
The major players covered in the Alosetron market are Abbott, Allergan, Takeda Pharmaceutical Company Ltd, AstraZeneca, SEBELA PHARMACEUTICALS, SYNERGY PHARMACEUTICALS, Bausch Health Companies Inc, Amneal Pharmaceuticals LLC, ardelyx, Par Pharmaceutical, among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-